학술논문
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
Document Type
Article
Author
Source
Subject
*DRUG efficacy
*LUNG diseases
*CHRONIC diseases
*MONOCLONAL antibodies
*CONGENITAL heart disease
*DISEASE incidence
*RANDOMIZED controlled trials
*RESEARCH funding
*DESCRIPTIVE statistics
*RESPIRATORY syncytial virus infections
*STATISTICAL sampling
*DRUG side effects
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2048-7193
Abstract
In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease. [ABSTRACT FROM AUTHOR]